1-5 of 5
Yuqi Chen
Close
Sort by
Journal Articles

Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study

Elias Jabbour, Ibrahim Aldoss, Shaun Fleming, Ashish Bajel, Paul Cannell, Monika Brüggemann, Gerhard Zugmaier, Joan Morris, Yuqi Chen, Sonny Powar, Hansen Wong, Björn Steffen, Hagop Kantarjian, Nicola Goekbuget
Journal: Blood
Blood (2022) 140 (Supplement 1): 6134–6136.
https://doi.org/10.1182/blood-2022-156080
Published: 2022
Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4077.
https://doi.org/10.1182/blood-2019-121708
Published: 2019
Journal Articles

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Yukio Kobayashi, MD DSc, Zachary F. Zimmerman, Iekuni Oh, MD PhD, Yoshinobu Maeda, MD PhD, Hironobu Minami, MD PhD, Toshihiro Miyamoto, MD PhD, Toru Sakura, PhD MD, Hiroatsu Iida, MD PhD, Yuqi Chen, PhD, Hitoshi Kiyoi, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5167.
https://doi.org/10.1182/blood-2018-99-112584
Published: 2018
Journal Articles

Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year

David J Kuter, MD DPhil, Adrian Newland, Beng H Chong, MBBS, PhD, Francesco Rodeghiero, MD, Monica Tejeda Romero, Ingrid Pabinger, MD, Yuqi Chen, Kejia Wang, Bhakti Mehta, Melissa Eisen
Journal: Blood
Blood (2017) 130 (Supplement 1): 1055.
https://doi.org/10.1182/blood.V130.Suppl_1.1055.1055
Published: 2017
Journal Articles

Baseline Biomarkers Influencing Clinical Outcomes in Adults with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Treated with Blinatumomab Versus Standard-of-Care Chemotherapy (SOC) from a Randomized Phase 3 Study

Andrew Wei, MBBS, PhD FRACP, FRCPA, Josep-Maria Ribera, MD, Giovanni Martinelli, Richard A. Larson, MD, David Ritchie, MD PhD, Armin Ghobadi, MD, Yuqi Chen, Cedric E. Dos Santos, Zachary F. Zimmerman, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2556.
https://doi.org/10.1182/blood.V130.Suppl_1.2556.2556
Published: 2017